In vitro activity of tigecycline and comparators against vancomycin-resistant enterococci from western Europe
Abstract number: R2290
Badal R., Johnson B., Bouchillon S., Hackel M., Johnson J., Hoban D., Dowzicky M.
Objectives: Tigecycline (TIG), a member of a new class of antimicrobials (glycylcyclines), has been shown to have potent expanded broad spectrum activity against most commonly encountered species responsible for community- and hospital-acquired infections. The T.E.S.T. Program determined the in vitro activity of tigecycline compared to amoxicillin-clavulanic acid, piperacillin-tazobactam, levofloxacin, ceftriaxone, linezolid (LZD), minocycline (MIN), vancomycin (VAN), ampicillin (AM), penicillin (PEN), and imipenem against vancomycin-resistant enterococci (VRE) collected from 94 hospitals in 22 Western European countries from 2004 through 2007.
Methods: 76 VRE (15 Enterococcus faecalis, 61 E. faecium) clinical isolates were identified to the species level at each participating site and confirmed by the central laboratory. Minimum Inhibitory Concentrations (MICs) were determined by the local laboratory using supplied broth microdilution panels and interpreted according to EUCAST guidelines (tigecycline susceptible <0.25 mg/L for enterococci).
Results:%S of all VRE to TIG, LZD, and MIN were 100, 100, and 71.7, respectively. For E. faecalis strains, the most active drugs were TIG (100%), LZD (100%), PEN (93.4%) and AM (93.3%). For E. faecium, the three most active drugs were TIG (100%), LZD (100%), and MIN (78.7%).
Conclusions: TIG exhibited outstanding activity against VRE, inhibiting 100% of strains at 0.25 mg/L with an MIC90 of 0.12 mg/L, which was 32-fold lower than the LZD MIC90 of 4 ml/L. The exceptionally broad spectrum of TIG, which includes many other multi-resistant Gram-positive and -negative bacteria in addition to VRE, should make it a very important addition to hospital formularies.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|